"Our studies provide the first proof-of-concept data
that a bivalent anthrax–plague vaccine can potentially protect vaccinees
in the event of a bioterror attack," with weaponized anthrax or plague bacteria,
the researchers wrote in the June 26 issue of the journal Frontiers in Immunology.